A phase 1/2 study of olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE): Results of the phase 1 study.

被引：1

作者：

McKay, Rana R.

Xie, Wanling

Ajmera, Archana

Saraiya, Biren

Parikh, Mamta

Folefac, Edmund

Olson, Adam C.

Choudhury, Atish Dipankar

Einstein, David Johnson

Heath, Elisabeth I.

Parikh, Rahul Atul

Kunos, Charles

Ivy, S. Percy

Shapiro, Geoffrey

Kurzrock, Razelle

机构：

[1] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Univ Calif San Diego, La Jolla, CA 92093 USA

[4] Rutgers Canc Inst New Jersey, Div Med Oncol, New Brunswick, NJ USA

[5] Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ USA

[6] UC Davis, Ctr Comprehens Canc, Sacramento, CA USA

[7] Ohio State Univ, Ctr Comprehens Canc, Div Med Oncol, Columbus, OH 43210 USA

[8] Duke Univ, Med Ctr, Durham, NC USA

[9] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[10] Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Oncol, Detroit, MI USA

[11] Univ Kansas, Med Ctr, Westwood, KS USA

[12] SUMMA Phys, Akron, OH USA

[13] NCI, Rockville, MD USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.e17020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e17020

引用

页数：3

共 50 条

[1] A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)
Pan, Elizabeth
Xie, Wanling
Ajmera, Archana
Araneta, Arlene
Jamieson, Christina
Folefac, Edmund
Hussain, Arif
Kyriakopoulos, Christos E.
Olson, Adam
Parikh, Mamta
Parikh, Rahul
Saraiya, Biren
Ivy, S. Percy
Allen, Eliezer M. Van
Lindeman, Neal I.
Kochupurakkal, Bose S.
Shapiro, Geoffrey I.
McKay, Rana R.
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (04) : 511 - 518
[2] Updated biomarker results from a phase 1/2 study of olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE).
Mckay, Rana R.
Xie, Wanling
Ajmera, Archana
Saraiya, Biren
Parikh, Mamta
Folefac, Edmund
Olson, Adam C.
Heath, Elisabeth I.
Parikh, Rahul Atul
Ivy, S. Percy
Mendel, Eliezer
Allen, Van
Lindeman, Neal Ian
Shapiro, Geoffrey
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[3] A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress
Jani, Chinmay
Xie, Wanling
Ajmera, Archana
Araneta, Arlene
Jamieson, Christina
Folefac, Edmund
Hussain, Arif
Kyriakopoulos, Christos
Olson, Adam C.
Parikh, Mamta
Parikh, Rahul Atul
Saraiya, Biren
Jabbour, Salma K.
Ivy, S. Percy
Van Allen, Eliezer Mendel
Lindeman, Neal Ian
Kochupurakkal, Bose
Shapiro, Geoffrey
McKay, Rana R.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[4] A phase I/II study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.
Shaya, Justin
Xie Wanling
Saraiya, Biren
Parikh, Mamta
Folefac, Edmund
Olson, Adam C.
Choudhury, Atish Dipankar
Einstein, David Johnson
Heath, Elisabeth I.
Parikh, Rahul Atul
Kunos, Charles
Ivy, Percy S.
LoRusso, Patricia
Kurzrock, Razelle
Shapiro, Geoffrey
McKay, Rana R.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[5] A Phase lb Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
Fong, Lawrence
Morris, Michael J.
Sartor, Oliver
Higano, Celestia S.
Pagliaro, Lance
Alva, Ajjai
Appleman, Leonard J.
Tan, Winston
Vaishampayan, Ulka
Porcu, Raphaelle
Tayama, Darren
Kadel, Edward E., III
Yuen, Kobe C.
Datye, Asim
Armstrong, Andrew J.
Petrylak, Daniel P.
CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4746 - 4756
[6] Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer
Armstrong, Andrew J.
Gupta, Santosh
Healy, Patrick
Kemeny, Gabor
Leith, Beth
Zalutsky, Michael R.
Spritzer, Charles
Davies, Catrin
Rothwell, Colin
Ware, Kathryn
Somarelli, Jason A.
Wood, Kris
Ribar, Thomas
Giannakakou, Paraskevi
Zhang, Jiaren
Gerber, Drew
Anand, Monika
Foo, Wen-Chi
Halabi, Susan
Gregory, Simon G.
George, Daniel J.
PLOS ONE, 2019, 14 (05):
[7] Fracture risk in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra 223)
Hijab, A.
Tunariu, N.
Tovey, H.
Alonzi, R.
Tree, A.
Staffurth, J.
Blackledge, M.
Padhani, A. R.
Stidwill, H.
Finch, J.
Chatfield, P.
Perry, S.
Koh, D-M.
Hall, E.
Parker, C.
ANNALS OF ONCOLOGY, 2020, 31 : S539 - S539
[8] Use of Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer
Parker, Chris
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (11) : 723 - 725
[9] A randomized phase 2 study investigating 3 dosing regimens of radium-223 dichloride (Ra-223) in bone metastatic castration-resistant prostate cancer (mCRPC).
Sternberg, Cora N.
Saad, Fred
Graff, Julie Nicole
Peer, Avivit
Vaishampayan, Ulka N.
Leung, Eugene
Rosenbaum, Eli
Gurney, Howard
Epstein, Richard
Davis, Ian D.
Wu, Bingyan
Trandafir, Lucia
Wagner, Volker Jean
Hussain, Maha
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[10] Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer
Choudhury, Atish D.
Kwak, Lucia
Cheung, Alexander
Allaire, Kathryn M.
Marquez, Jaqueline
Yang, David D.
Tripathi, Abhishek
Kilar, Jacqueline M.
Flynn, Meredith
Maynard, Brianna
Reichel, Rebecca
Pace, Amanda F.
Chen, Brandon K.
Van Allen, Eliezer M.
Kilbridge, Kerry
Wei, Xiao X.
Mcgregor, Bradley A.
Pomerantz, Mark M.
Bhatt, Rupal S.
Sweeney, Christopher J.
Bubley, Glenn J.
Jacene, Heather A.
Taplin, Mary-Ellen
Huang, Franklin W.
Harshman, Lauren C.
Fong, Lawrence
CANCER IMMUNOLOGY RESEARCH, 2024, 12 (06) : 704 - 718

← 1 2 3 4 5 →